KALA BIO (NASDAQ:KALA – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($1.93) EPS for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50, Zacks reports.
KALA BIO Price Performance
KALA BIO stock traded down $0.29 during mid-day trading on Wednesday, reaching $6.80. 31,046 shares of the company’s stock were exchanged, compared to its average volume of 84,364. The business’s fifty day simple moving average is $5.97 and its 200 day simple moving average is $6.29. KALA BIO has a one year low of $4.21 and a one year high of $10.97. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.07 and a current ratio of 3.07.
Wall Street Analyst Weigh In
Separately, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of KALA BIO in a research report on Monday, August 19th.
KALA BIO Company Profile
KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Recommended Stories
- Five stocks we like better than KALA BIO
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Rocket Lab is the Right Stock for the Right Time
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
